卡那单抗治疗家族性地中海热:AIDA网络真实世界数据显示快速持久控制与完全缓解概率
基于AIDA国际注册网络158例家族性地中海热(FMF)患者的真实世界数据,评估卡那单抗(CAN)实现完全临床-实验室缓解的有效性。结果显示3个月完全缓解率45.6%,12个月58.6%,末次随访55.2%;超过80%患者各时间点无临床表现,炎症标志物3个月内显著正常化,因无效停药罕见(≤6%)。
要点
- 卡那单抗在FMF中可实现快速持久临床与实验室控制,3个月完全缓解率45.6%。
- 完全缓解与复发-缓解病程及较少年发作次数相关,早期应答可能预示更好长期结局。
- 因无效停药率≤6%,绝大多数患者器官损伤评分稳定。
核心结论
- 卡那单抗在FMF中能有效实现快速且持久的临床和实验室控制,包括严格的完全缓解终点。
- 早期有效性可能有利于更好的长期结局,但延迟达到完全缓解和实验室完全控制并不少见。
- 本研究证实卡那单抗是FMF有效且持久的治疗选择。
研究设计与样本
- 数据来自国际自身炎症性疾病联盟(AIDA)网络注册库,该库专门收录单基因自身炎症性疾病。
- 评估包含回顾性和前瞻性真实世界数据,共纳入158例接受卡那单抗治疗的FMF患者。
主要发现
- 完全临床-实验室缓解率在3个月时为45.6%,12个月时为58.6%,末次随访时为55.2%(平均治疗时长45个月)。
- 部分缓解率在相同时间点分别为16.5%、12.5%和16.8%。
- 各时间点超过80%的患者完全无临床表现,炎症标志物在3个月评估时显著正常化。
- 早期(3个月内)达到完全缓解和实验室完全控制的患者维持这些结局的概率更高,但其他患者中概率仍可观。
- 完全缓解与复发-缓解病程及较少年发作次数相关,几乎所有患者器官损伤评分保持稳定,因无效停药罕见(≤6%)。
关键数值与推荐
- 完全临床-实验室缓解定义为实现主要疾病表现完全控制和实验室炎症标志物完全正常化。
- 完全临床-实验室缓解率:3个月45.6%,12个月58.6%,末次随访55.2%。
- 部分缓解率:3个月16.5%,12个月12.5%,末次随访16.8%。
- 因无效停药率≤6%。
临床怎么用
- 卡那单抗可用于FMF患者实现快速持久的临床和实验室控制,包括严格的完全缓解目标。
- 早期(3个月内)达到完全缓解和实验室完全控制可能预示更好的长期维持概率。
- 延迟达到完全缓解和实验室完全控制并不少见,不应因此过早判定治疗无效。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the effectiveness of canakinumab (CAN) in controlling clinical and laboratory inflammation by achieving complete control of cardinal disease manifestations and full normalization of laboratory inflammatory markers. METHODS: Data were obtained from the international AutoInflammatory Disease Alliance (AIDA) network registry, dedicated to monogenic autoinflammatory diseases. The assessment included both retrospective and prospective real-world data. RESULTS: In total, 158 FMF patients treated with CAN were enrolled. Complete clinical-laboratory response was observed in 45.6% of patients at 3 months, 58.6% at 12 months and 55.2% at the last follow-up, after a mean treatment duration of 45 months. Partial response occurred in 16.5%, 12.5% and 16.8% at the same timepoints, respectively. Complete absence of clinical manifestations was observed in more than 80% of patients at each timepoint. Inflammatory markers normalized significantly by the 3-month assessment. The probability of achieving and maintaining complete response and full laboratory control appeared higher in patients reaching these outcomes by 3 months, although it remained substantial in other patients as well. Complete response was associated with a relapsing-remitting disease course and fewer annual attacks. Nearly all patients maintained stable organ damage scores, and therapy discontinuation due to inefficacy was rare (≤6%). CONCLUSION: CAN is effective in achieving rapid and sustained clinical and laboratory control in FMF, including stringent endpoints of complete response. Early effectiveness may favour better long-term outcomes, but delayed achievement of complete response and full laboratory control is not uncommon. This study confirms CAN as an effective, and durable therapeutic option in FMF.
引用
- Vitale A, Caggiano V, Sbalchiero J, et al. Effectiveness and probability of full disease control with canakinumab in familial Mediterranean fever: real-world data from the AIDA Network. Rheumatology (Oxford). 2026. PMID: 42444147. doi:10.1093/rheumatology/keag361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。